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W. Dowdle. Tark Forcefor Child Survival and Development, Decatur, 
G A ,  USA 
Eradication has been variously defined, hut, in essence, is the absence 
of a disease agent in nature as the result of deliberate control efforts. 
Intervention efforts are no longer needed. Smallpox is the only 
infectious disease that has been eradicated. Immunization against 
smallpox is no longer practiced. Programs are underway to eradicate 
poliovirus and Guinea worm. Previous eradication programs 
targeting malaria, yellow fever and yaw failed to achieve their goals, 
but led to better understanding of the biological, social, political and 
economic complexities of disease eradication. Distinct biological 
features and operational factors define eradicability. Three criteria are 
of primary importance: (1) effective intervention is available to 
interrupt transmission of the agent; (2) practical, sensitive and specific 
magnostic tools are available to detect infection that can lead to trans- 
mission; and (3) humans are essential for the agent life cycle. 
Eradication is the ultimate goal of every effective public-health 
program, whether stated or not. Fundamental issues relate to specific 
versus comprehensive goals and time-limited versus long-term goals. 
Biological plausibility is but one of the factors to consider. Deciding 
on the appropriate eradication goal also requires careful evaluation of 
cost-effectiveness, resource availability, and political will. All of these 
issues are now under discussion for several proposed potential 
candidates for eradication: measles, rubella, onchocerciasis, and 
lymphatic filariasis. A time-limited eradication goal is a major 
commitment and an awesome responsibility, with no room for 
failure. Eradication programs work best where health system infra- 
structures are strong. Where infrastructures are weak, eradication 
programs can be powerful building tools. 
IS160] Measles and poliomyelitis eradication: the 
protagonists for global eradication 
C. de Quadros. Pan American Health Org., Program kccines atid 
Immunirat.,  Washington, D.C., USA 
In September 1985, PAHO targeted poliomyelitis to be eradicated 
from the Americas by 1990. The strategy for poliomyelitis eradication 
included routine vaccination with oral poliomyelitis vaccine (OPV), 
complemented by national immunization days (NIDs) with OPV, 
aimed at rapidly interrupting chains of transmission. The NIDs, and 
surveillance for detection of cases of acute flaccid paralysis (AFP) with 
laboratory investigation for the presence of wild poliovirus in their 
stools, proved to be two key components of eradication. The third 
key component of the strategy was the implementation of special 
‘mop-up’ operations of house-to-house OPV vaccination in those 
few municipalities where poliomyelitis was still prevalent. The 
Americas were certified polio-free in September 1994 and by July 
1996. Over 7 years have elapsed since the last confirmed case of 
paralytic poliomyelitis due to wild poliovirus was detected on 23 
August 1991, in Peru. This fact is of historical significance in the 
annals of public health, and the strategies developed by PAHO are 
now being implemented worldwide for the achievement of polio 
eradication by the year 2000. During 1998 there were less than 5000 
cases reported worldwide, the lowest number ever reported, and the 
target of global eradication by the year 2000 is well in our grasp. With 
poliomyelitis eradicated from the Americas, countries set the target 
of eradication of measles from the Western Hemisphere by the year 
2000. Strategies recommended by PAHO to achieve this goal include 
national immunization campaigns conducted in a short period of 
time, usually 1 month, aimed at immunizing all children between 1 
year and 15 years of age with measles vaccine regardless of previous 
vaccination status, and maintenance of high immunization levels in 
the new cohorts of newborns. These campaigns, aiming at inter- 
rupting all chains of transmission, are followed by intense surveillance 
of suspected measles cases, prompt investigation and outbreak 
prevention whenever a confirmed case of measles occurs. As a result 
of implementation of this strategy, only 2109 confirmed measles cases 
were reported in 1996, the lowest number of total measles czes since 
measles surveillance began in the Americas. In the English-speaking 
Caribbean, it has now been over 6 years since the last laboratory- 
confirmed case. No cases of measles have been reported for the past 
4 years in Cuba and Chile, and present surveillance systems are unable 
to detect measles cases in most countries of the region. An obstacle 
to measles eradication is the accumulation of susceptible children 
which occurs among 1-5-year-olds because the vaccine is not 100% 
efficacious and coverage never reaches 100%. To prevent this 
accumulation of susceptibles and prevent outbreaks, PAHO recom- 
mends that countries undertake ‘follow-up’ vaccination campaigns 
targeting all children 1-5 years of age, regardless of previous vaccina- 
tion status, every 4-5 years. The absence of ‘follow-up’ campaigns in 
some few countries or areas in the Americas resulted in an outbreak 
of measles in Brazil in 1997, following a possible importation from 
Europe, and in Argentina in 1998, following an importation from the 
outbreak in Brazil. In total, over 50 000 cases occurred in the 
Americas in 1997, over 95% in Brazil, and nearly 10 000 in 1998, 
over 85% in Argentina. By now, these outbreaks are under control 
and the target of eradication by the year 2000 is expected to be 
achieved. As was the case with smallpox, the examples of polio and 
measles demonstrate that humankind can conquer other diseases. 
However, much remains to be done, and there is therefore a need for 
continuous political commitment, which should be translated into 
allocation of resources. Participation and collaboration of all sectors 
of society in every country will be fundamental for the achievement 
of these objectives. The success of measles eradication in the 
Americas will set the stage for the global eradication of this disease 
in the first decade of the 21st century. 
Can malaria be globally eradicated? 
C.G. Meyer. Institatfir Tropenmedizin, Berlin, Germany 
Malaria is a major global health problem and Plasmodium falciparum 
malaria remains a leading cause of mortality in many tropical 
countries. Nearly half of the world’s population is under continuous 
threat from malaria, with an estimated 400-500 million clinical cases 
and more than 2 million deaths occurring every year. The situation 
is complicated by the emergence and spread of resistance to many 
antimalarial drugs. In addition to good treatment facilities in areas of 
high transmission, chemoprophylaxis in pregnancy, use of insecticide- 
treated bednets and household spraying, vaccination is primarily 
considered to supplement current strategies of disease prevention and 
control. 
After the availability of Plasmodium falciparum cultivation and the 
analysis of parasite antigens with successful protection of mice and 
monkeys following immunization with distinct antigens, several 
human vaccination trials have failed so far to provide sufficient 
protective immunity. Other approaches are now under study, with 
some 20 candidate molecules and DNA vaccines being tested. Target 
antigens are pre-erythrocyte and erythrocyte stages, gametes, and 
pathogenic parasitic metabolites. A major obstacle is the complexity 
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of the antigenic structure of  the parasite, with large numbers of 
different epitopes that are, in part, stage-specific and, furthermore, 
may vary between strains. Adjuvants also influence the type of 
iinniune response. The  growing knowledge of pathogenesis, and 
host-dependent genetic and ininiunologic factors involved in the 
clinical outcome of I-) -falciparrm malaria, and the insight into the 
paracite's evasion iiiechanisiiis, help us to understand the interactions 
of this infectiou, agent with the host's immune system. We now 
believe that malaria vaccines will eventually be available. We do not, 
however, believe that vaccines alone will lead to the eradication of 
this disease. 
The future of global strategies for vaccination: 
WHO perspectives 
P-H. Lainbert. WHO, Vaccine Research G Devel. Uirit, Gencua, 
Switrt~rlarid 
Future vaccination strategies will certainly be related to the potential 
impact of vaccination on  morbidity and mortality directly or 
indirectly associated with specific infectious diseases. About 1.8 
rnillion children die of infection in the neonatal period (0-4 weeks 
of age), particularly in Asia and Africa. The main causes of death are 
bacterial infections caused by Staphylococctrs aurerrs, group A strepto- 
cocci, Streptococcus pnerimoniae, Gram-negative coliforriis and 
Saltnoriella as well as neonatal tetanus. During the post-neonatal 
period (1-12 months), severe infant infections are responsible for over 
2 million deaths. In the developing world, the major causes are acute 
respiratory infections due to pneumococci, Haenmphihrs iqfluenzae or 
pertussis as well as diarrhea caused by rotaviruc, shigella, Salmonella 
or E. coli. This contrasts with the greater importance of respiratory 
viruses (RSV, parainfluenza and influenza), urinary infections, and 
rotavirus diarrhea in industrialized countries. Although a number of 
new vaccines are now becoming available to meet this challenge, 
Vaccination strategies to prevent early-life infectious diseases should 
he selected and adapted accordingly. They will include maternal 
immunization for early neonatal infections, as well as vaccination in 
early infancy (0-3 months) for early-occurring diseases. Problem to 
be solved are inainly related (1) to safety issues (maternal or neonatal 
immunization), (2) to inniiunologic immaturity and T-cell polariz- 
ation (0-3 months imiiiunization), (3) to the duration of induced 
protection and iiieniory, and (4) to inhibition of infant responses by 
maternal antibodies. 
Recent developments in cardiovascular 
infections 
Do w e  still need prophylaxis against infective 
endocarditis? 
E. Gutschik. Departittent qf Clinical Minobiolosy, Eispe&jcR Hospital, 
Urriversiry qf C o p c i i h a p ~ ,  Coprnhapi, Deninark 
The answer is yes, even according to a recent population-based, case- 
control study from Philadelphia, USA (Ann Intern Med 1998;129: 
761-9) challenging the current recomniendations for prophylaxis for 
infective endocarditis (1E). The findings indicate that dental treat- 
ment is not a risk factor. However, differences in dental health, dental 
status and dental care between case patients and controls were not 
considered. This study will not change our attitude towards the 
necessity for antimicrobial prophylaxis. but underlines the need for 
data regarding the correlation between the magnitude of bactereiiiia 
(CFU/inL blood) in connectio~i with dental procedures and the 
incidence of IE. It is likely that prophylaxis should be downgraded 
to 'not recommended' for some dental procedures. Since oral micro- 
organisms are still responsible for most ca5es of IE, it is obvious that 
prevention should be upgraded, with maintenance of better dental 
care in patients at risk for 1E. Prophylaxis 111 children, espccially with 
major congenital heart conditions, requires further investigation and 
discussions. Prevention of  nosoconiial endocarditis represent\ a 
formidable clinical challenge, with the introduction of new card~ic  
devices like implantable cardiovascular defibrillators and left ventri- 
cular assist devices, raising questions of hardware removal in casec of 
infection or chronic suppressive antimicrobial therapy. The  incidence 
and mortality of prosthetic valve endocarditis are still unacceptably 
high. Here also we should focus on prevention (surgical tcchniquec, 
surgical materials, treatment of perioperative bacteremias, dental 
health) rather than efforts to amplify antimicrobial prophylaxis. 
New antibiotic treatment modalities 
J.M. Entenza, J. Vouillanioz, M.P. Glauser, I! Moi-eillon. fr~firrrtirrs 
Diseases, CHUY L a u s a r m ,  Suitrrrlarrd 
Treatment of Staplrylocorcirs a i m u s  and streptococcal endocarditis 
require5 prolonged administration of pareliteral p-lactani\ or vanco- 
niycin. Newer quinoloiies are active against Gram-positive bacteria, 
are well absorbed after oral administration. and have .i pi-olonged 
seruiii f l / 2 ,  allowing once-daily dosage. Levofloxacin, trovafloxacin 
and moxifloxacin were tested in rats with S. awc'irs or streptococcal 
experimental endocarditis (EE). They were compared to cipro- 
floxacin (Cipro) and vancomyciii (Vanco) for S. O I I Y C I I > ,  or ceftriaxone 
for streptococci. The risk of resistance selection was exmiiried. 
Against Cipro-susceptible S. atireus, all three new quinolones wzrc 
equivalent or  more active than Cipro and Vanco in vitro ~ n d  in VIVO, 
and were markedly less prone than Cipro to select for quinolone 
resistance. However, they were ineffective against S .  m r w s  alreddy 
resistant to Cipro. Two experimental quinolones (Y-688 . Ind S- 
34109) with high in vitro activity against Cipro-resistant S. airreics also 
failed in rats, arid selected for mutants with increased MICc. Thu\, 
once resistant to Cipro, S. aweus may eady  acquire addltioii3~ iiiutzl- 
tions, making it resistant to the most powerful quinolones. Against 
streptococci, levofloxacin was etfective against EE due to penicillin- 
susceptible and -resistant isolates. [n contrast, trovafloxacin failed in 
similar experiments. Time-kill experiments indicated that very low 
concentrations (X2 and X4 MIC) oflevofloxacin were more bacteri- 
cidal than trovafloxacin against streptococci, suggestmg that higher 
doses of this drug should be used in thir situation. This was not 
observed for S. aureus. We conclude that newer quinolones might be 
convenient and effective against Cipro-susceptible (but not -resictant) 
S. anreus and streptococcal infections. Moreover, they are lesc prone 
than older quinolones to select for resistance. 
[s1651 Anti-infective impregnation of vascular 
prostheses and cardiac prosthetic valves: 
rationale and experimental evidence 
J. Steckelberg, Mayo Clirric, I r $ ~ t i i ~ u ~  Disrascs arid Iritcrrral Afedicirw. 
Roriiestev, Mh: USA 
Anti-infective agents have been bound to a v3riety of iiiiplantable or  
indwelling medical devices in an attempt to increasc local concc~i- 
trations of antiiiiicrobial or antiseptic agent\ and to reduce the I-nk o f  
foreign body infections. This approach has been shown to be success- 
ful in some clinical settings (such a\ silver-coatzd intrava\cular 
catheters) but unsuccessful in others. For the prevention or trcatiiiciit 
